Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma.
Dimitra KerdidaniPanagiotis ChouvardasAres Rocanin ArjoIoanna GiopanouGiannoula NtaliardaYu Amanda GuoMary TsikitisGeorgios KazamiasKonstantinos PotarisGeorgios T StathopoulosSpyros ZakynthinosIoannis KalomenidisVassili SoumelisGeorge KolliasMaria TsoumakidouPublished in: Nature communications (2019)
Lung adenocarcinoma (LUAD)-derived Wnts increase cancer cell proliferative/stemness potential, but whether they impact the immune microenvironment is unknown. Here we show that LUAD cells use paracrine Wnt1 signaling to induce immune resistance. In TCGA, Wnt1 correlates strongly with tolerogenic genes. In another LUAD cohort, Wnt1 inversely associates with T cell abundance. Altering Wnt1 expression profoundly affects growth of murine lung adenocarcinomas and this is dependent on conventional dendritic cells (cDCs) and T cells. Mechanistically, Wnt1 leads to transcriptional silencing of CC/CXC chemokines in cDCs, T cell exclusion and cross-tolerance. Wnt-target genes are up-regulated in human intratumoral cDCs and decrease upon silencing Wnt1, accompanied by enhanced T cell cytotoxicity. siWnt1-nanoparticles given as single therapy or part of combinatorial immunotherapies act at both arms of the cancer-immune ecosystem to halt tumor growth. Collectively, our studies show that Wnt1 induces immunologically cold tumors through cDCs and highlight its immunotherapeutic targeting.
Keyphrases
- stem cells
- dendritic cells
- cell proliferation
- genome wide
- regulatory t cells
- immune response
- gene expression
- transcription factor
- endothelial cells
- squamous cell carcinoma
- young adults
- induced apoptosis
- climate change
- dna methylation
- drug delivery
- mesenchymal stem cells
- risk assessment
- oxidative stress
- squamous cell
- binding protein
- cell therapy
- endoplasmic reticulum stress
- papillary thyroid